Advaxis Inc
F:FAD2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
US |
|
Ishikawa Seisakusho Ltd
TSE:6208
|
JP |
|
KKR & Co Inc
NYSE:KKR
|
US |
|
L
|
Landing International Development Ltd
HKEX:582
|
HK |
|
Shenzhen H&T Intelligent Control Co Ltd
SZSE:002402
|
CN |
|
C
|
Componenta Oyj
OMXH:CTH1V
|
FI |
|
Mrs. Bectors Food Specialities Ltd
NSE:BECTORFOOD
|
IN |
Advaxis Inc
Total Assets
Advaxis Inc
Total Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Advaxis Inc
F:FAD2
|
Total Assets
$16.6m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Assets
$134B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Assets
$59B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Assets
$90.6B
|
CAGR 3-Years
12%
|
CAGR 5-Years
8%
|
CAGR 10-Years
2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Assets
$25.6B
|
CAGR 3-Years
12%
|
CAGR 5-Years
17%
|
CAGR 10-Years
26%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Assets
$40.6B
|
CAGR 3-Years
12%
|
CAGR 5-Years
19%
|
CAGR 10-Years
22%
|
|
Advaxis Inc
Glance View
Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. The company is headquartered in Monmouth Junction, New Jersey and currently employs 15 full-time employees. The company went IPO on 2005-07-28. The Company’s products are based on a platform technology, which utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. The company is focused on single antigen and multiple antigen delivery products. The firm's pipeline of product candidates includes ADXS-503, which develops for treatment of non-small cell lung cancer; ADXS-504, which develops for the treatment of early-stage prostate cancer; and ADXS-PSA, which develops for the treatment of metastatic prostate cancer. Its ADXS-503 and ADXS-503 are in Phase I clinical trial. ADXS-PSA is in Phase II clinical trial. The company has completed and closed out clinical studies of Lm Technology immunotherapies in three program areas, HPV associated cancers, Personalized neoantigen-directed therapies and PSA directed therapy.
See Also
What is Advaxis Inc's Total Assets?
Total Assets
16.6m
USD
Based on the financial report for Dec 31, 2023, Advaxis Inc's Total Assets amounts to 16.6m USD.
What is Advaxis Inc's Total Assets growth rate?
Total Assets CAGR 5Y
-27%
Over the last year, the Total Assets growth was -64%. The average annual Total Assets growth rates for Advaxis Inc have been -31% over the past three years , -27% over the past five years .
